Previous 10 | Next 10 |
2023-10-05 10:00:20 ET More on Health Care Select Sector SPDR BofA Securities: Which small cap non-earner stocks to avoid Citi turns cautious on pharmaceuticals and biotech For further details see: Orchard Therapeutics, Longeveron among healthcare movers
Shares of Orchard Therapeutics PLC (NASDAQ: ORTX) traded at a new 52-week high today and are currently trading at $15.94. So far today, approximately 5.04M shares have been exchanged, as compared to an average 30-day volume of 101.26k shares. Orchard Therapeutics PLC, a biopharmaceutical comp...
2023-10-05 08:54:18 ET Orchard Therapeutics ( NASDAQ: ORTX ) +97% . Grom Social Enterprises ( GROM ) +29% . Janover ( JNVR ) +19% Drives Lender Growth on its Fintech Marketplace. Femasys ( FEMY ) +18% Femasys Inc. to ...
2023-10-05 05:48:00 ET NASDAQ: RIVN plunged more than 9% Related stories BlackBerry Limited (BB) Q2 2024 Earnings Call Transcript Does Rivian Still Have An Existential Crisis? BlackBerry Earnings Preview: Pre-Announcement May Not Save Further Sell-Off ...
2023-10-05 05:24:47 ET More on both companies Orchard Therapeutics: A Reassessment Orchard Therapeutics: Highly Valued Once, Undervalued Today Orchard Therapeutics stock jumps 13% as FDA accepts BLA for OTL-200 For further details see: Kyowa Kirin to buy ...
-Orchard Therapeutics is a global gene therapy leader with experience successfully developing and commercializing medicines for rare diseases- -Acquisition enriches Kyowa Kirin’s portfolio, enables the development of numerous promising candidates with a clinically differentiated plat...
2023-09-20 07:52:00 ET More on Orchard Therapeutics Seeking Alpha’s Quant Rating on Orchard Therapeutics Historical earnings data for Orchard Therapeutics Financial information for Orchard Therapeutics Orchard Therapeutics: A Reassessment Orcha...
2023-09-18 15:13:48 ET Orchard Therapeutics ( NASDAQ: ORTX ) stock jumped 13% in afternoon trading Monday after the company said that its Biologics License Application for its drug OTL-200 had been accepted by the FDA under its priority review program, with a decision expected by Ma...
2023-09-18 09:20:41 ET Summary Orchard Therapeutics plc is a London-based biotech company focused on developing gene therapies for rare diseases. The company's lead therapy, OTL-200, has received marketing authorization in Europe for the treatment of metachromatic leukodystrophy. ...
PDUFA date set for March 18, 2024 OTL-200 would be the first and only treatment in the U.S. for early-onset MLD Previously published data demonstrated administration of one-time gene therapy enables sustained preservation of motor function and cognitive development BOSTON ...
News, Short Squeeze, Breakout and More Instantly...
Orchard Therapeutics plc Company Name:
ORTX Stock Symbol:
NASDAQ Market:
Orchard Therapeutics plc Website:
TOKYO, LONDON and BOSTON, May 03, 2024 (GLOBE NEWSWIRE) -- Orchard Therapeutics, recently acquired by Kyowa Kirin with the goal of accelerating the delivery of new gene therapies to patients around the globe, today announced that Bobby Gaspar, M.D., Ph.D., co-founder and chief executive officer, ...
Crescent Energy Company Class A (CRGY) is expected to report $0.21 for Q4 2023 ThredUp Inc. (TDUP) is expected to report $-0.13 for Q4 2023 Wright Investors` Service Holdings Inc (IWSH) is expected to report for Q4 2023 Bridgford Foods Corporation (BRID) is expected to report for Q1 2...
Gene therapy being developed as a one-time treatment to address the underlying cause of the disease by inserting a functional copy of the human IDUA gene into a patient’s own hematopoietic stem cells HURCULES study to enroll 40 patients at clinical sites across the U.S....